)
Visual
test
Haemonetics
Haemonetics (HAE) investor relations material
Haemonetics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Feb, 2026
Executive summary
Q3 revenue was $339M, down 2.7% year-over-year, with year-to-date revenue at $988M; organic ex-CSL revenue grew 7.5% year-over-year.
Net income for Q3 was $44.7M, up 19.3% year-over-year; adjusted EPS increased 10% to $1.31.
Gross margin improved to 59.7% (up 420 bps); adjusted gross margin was 60.2% (up 250 bps).
Strong performance in Plasma and Blood Management Technologies, with ongoing innovation and portfolio transformation supporting margin expansion.
Recent acquisitions, including Vivasure Medical, expanded the interventional technologies portfolio; share repurchases continued.
Financial highlights
Q3 operating income was $67.4M (19.9% margin), up from $59.0M (16.9%) last year; adjusted operating margin was 26.3%.
Q3 net income margin was 13.2%; adjusted net income margin was 18.1%.
Free cash flow for Q3 was $74.2M, up 151% year-over-year; free cash flow conversion reached 121%.
Cash and cash equivalents at quarter-end were $363M, up from $307M sequentially.
Net leverage ratio improved to 2.37x EBITDA; long-term debt stood at $920M.
Outlook and guidance
Full-year reported revenue guidance updated to a decline of 1%-3%; organic revenue guidance at 0-2%.
Organic revenue guidance ex-CSL increased to 8%-10%; Plasma segment organic ex-CSL growth guidance raised to 17–19%.
Adjusted EPS guidance for FY26 raised to $4.90–$5.00.
Free cash flow guidance increased to $200–$220M, with conversion expected to exceed 80%.
Hospital business expected to deliver ~4% growth at the low end of prior range.
Drivers of Plasma organic growth ex-CSL
What is the strategy for Interventional Tech growth?
How did lower inventory purchasing boost cash flow?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebPECO
2026 FFO per share growth guided at 5.5% with record occupancy and robust acquisitions. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRIRevenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects.
- 6 FebNVDA
AI-driven digital twins and real-time simulation will transform engineering and manufacturing. - 6 FebTUPRS
Net income reached TRY 29.5 billion, with strong dividends and a robust net cash position. - 6 FebCPT
2025 results beat guidance; Sun Belt focus, asset sales, and share buybacks drive 2026 strategy. - 6 FebCRIH1 2025 saw a return to profit, record revenues, and strong cash from major space projects.
Next Haemonetics earnings date
Q4 20267 May, 2026
Haemonetics
Next Haemonetics earnings date
Q4 20267 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Haemonetics Corporation provides hematology products and solutions. The company offers blood and plasma collection systems to collect, process, and return blood to the patient; surgical blood salvage systems to safely and effectively collect and re-infuse patients' own red blood cells that would otherwise be discarded during surgery; and transfusion administrations systems, including software, disposables and data management services to help hospitals operate their transfusion processes, and effectively manage the complications associated with patient blood management. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage